Endocrinology Medical News about 18F-FDG PET

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Predictive value of ¹⁸F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors
The Journal of Nuclear Medicine, 05/15/09

Garin E et al. – Findings show that ¹⁸F-FDG PET exhibits excellent predictive values for early tumor progression; ¹⁸F-FDG PET and somatostatin receptor scintigraphy (SRS) results correlate with progression-free survival and overall survival even for histologically low-grade tumors.

Methods

Study to investigate whether ¹⁸F-FDG PET and SRS can predict early disease progression and patient survival
A prospective study of pts with metastatic neuroendocrine tumor diagnosed between Sep 2003 and Jan 2006
CT, SRS, and ¹⁸F-FDG PET were performed and histologic data reviewed
CT was repeated every 3 mo to assess the risk of early progressive disease, PFS, and OS

Results

38 pts; mean age, 60 ± 15 yrs; 4 pts had a high-grade and 34 a low-grade tumor
Results of ¹⁸F-FDG PET and SRS were positive in 15 and 27 pts
The 2-yr OS and PFS were 73% and 45%; 16 pts had early progressive disease.
Most ¹⁸F-FDG PET-positive pts and SRS-negative pts had early progressive disease
¹⁸F-FDG PET gave excellent negative and positive predictive values of 91% and 93%
¹⁸F-FDG PET results correlated with PFS and OS even when only low-grade tumors were considered
SRS was associated with PFS and OS
Multivariate analysis: only 18F-FDG PET was predictive of PFS